RTP Mobile Logo
Select Publications

Abramson JS et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. ASH 2019;Abstract 241.

Adkins S. CAR T-cell therapy: Adverse events and management. J Adv Pract Oncol 2019;10(suppl 3):21-8. Abstract

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 2016;127(26):3321-30. Abstract

Buechner J at al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Update to the interim analysis. EHA 2017;Abstract S476.

Hay KA et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017;130(21):2295-306. Abstract

Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotech 2013;31(11):999-1008. Abstract

Jacobson CA et al. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). ASCO 2020;Abstract 8008.

Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract

Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract

Maude SL. CAR emissions: Cytokines tell the story. Blood 2017;130(21):2238-40. Abstract

Maude SL et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371(16):1507-17. Abstract

Munshi NC et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. ASCO 2020;Abstract 8503.

Neelapu SS et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. ASH 2019;Abstract 203.

Neelapu SS et al. Chimeric antigen receptor T-cell therapy - Assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47-62. Abstract

Neelapu SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Eng J Med 2017;377(26):2531-44. Abstract

Perez A et al. Pharmacodynamic profile and clinical response in patients with B-cell malignancies of anti-CD19 CAR T-cell therapy. ASH 2015;Abstract 2042.

Riegler LL et al. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag 2019;15:323-35. Abstract

Schuster SJ et al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 2020;4(7):1432-9. Abstract

Tai YT et al. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7(11):1187-99. Abstract

van der Steegen SJC et al. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14(7):499-509. Abstract

Wang M et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Eng J Med 2020;382(14):1331-42. Abstract

Wang ML et al. KTE-X19, an anti-cd19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): Results of the phase 2 ZUMA-2 study. ASH 2019;Abstract 754.